Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Development of T Cell Receptors and Chimeric Antigen Receptors Into Therapeutics for Adoptive Transfer in Humans To Treat Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 23, 2012 will be considered, in addition to the current non- exclusive applications under consideration, for the prospective license territory and field of use to be granted under the contemplated exclusive patent license.
View Prospective Grant of Exclusive License: Use of Methanocarba Analogues of Purine and Pyrimidine Nucleosides and Nucleotides to Treat or Prevent Cardiac Diseases in Humans Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 11, 2012 will be considered.
View Prospective Grant of Exclusive License: Veterinary Biological Products for Swine Influenza Vaccines Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before January 20, 2012 will be considered.
View Prospective Grant of Exclusive License: Avian Influenza Vaccines for Domesticated Poultry/Wild Birds To Be Provided to the National Veterinary Stockpile Program and Avian Influenza Vaccines To Be Sold as Veterinary Biological Products Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before January 5, 2012 will be considered.
View Prospective Grant of Exclusive License: Use of Agents Targeting Thrombospondin-1 and CD47 To Treat Radiation-Induced Damage and Enhance the Effectiveness of Radiotherapy in Cancer Patients Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 9, 2012 will be considered.
View Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 19, 2011 will be considered.
View Prospective Grant of Exclusive License: Electron Paramagnetic Resonance Devices and Systems for Oximetry Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before November 15, 2011 will be considered.
View Government-Owned Inventions; Licensing and Collaborative Research Opportunity for PANVAC-Cancer Vaccine for the Prevention and Treatment of Colorectal Cancer
View Prospective Grant of Exclusive License: The Development of a Companion Diagnostic Kit for Predicting Therapeutic Efficacy of Anti-Cancer Agents Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 21, 2011 will be considered.
View Prospective Grant of Exclusive License: Secreted Frizzled Related Protein-1 (sFRP-1) and derivatives thereof and their Use In Therapeutic Applications Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2011 will be considered.
View Prospective Grant of Exclusive License: The Development of Human Anti-Mesothelin Monoclonal Antibodies for the Treatment of Human Cancers Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2011 will be considered.
View Prospective Grant of Exclusive License: Compositions and Method for Preventing Reactogenicity Associated with Administration of Immunogenic Live Rotavirus Compositions Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 31, 2011 will be considered.
View Prospective Grant of Exclusive License: Conjugate Vaccines Against B. anthracis (Anthrax) and Monoclonal Antibodies Against Anthrax Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 26, 2011 will be considered.
View Prospective Grant of Exclusive License: Devices for Clearing Mucus From Endotracheal Tubes Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before September 23, 2011 will be considered.
View Prospective Grant of Exclusive License: Use of PKM2 Activators for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 7, 2011 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License; The Development of Ulipristal Acetate for the Treatment of Symptomatic Uterine Fibroids Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2011 will be considered.
View Prospective Grant of Exclusive License; Devices for Clearing Mucus From Endotracheal Tubes Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before July 22, 2011 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Granting of an Exclusive License 10/24/2005.
View Prospective Grant of Exclusive License: Device and System for Two Dimensional Analysis of Biomolecules From Tissue and Other Samples Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2011 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 31, 2011 will be considered.
View Cancer Therapy Evaluation Program Intellectual Property Option to Collaborator
View Prospective Grant of Exclusive License: Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 11, 2011 will be considered.